Analyst Recommends Selling Novo Nordisk Amid Rising Competition and Slowing Sales

This financial analysis evaluates whether investors should buy, sell, or hold Novo Nordisk stock at its current price of approximately $46. The article highlights that Novo Nordisk has underperformed the S&P 500 index in 2026, losing 7.5% while the broader market gained 8%. Although weight loss and diabetes treatments like Wegovy and Ozempic constitute over three-quarters of the company's sales, signs of market saturation and competition are emerging. Specifically, Ozempic sales declined by 8% year-over-year in the first quarter. The analyst points to intensifying competition from rivals such as Eli Lilly, which received FDA approval for its oral treatment Foundayo, and Pfizer, which expanded its pipeline by acquiring Metsera. Due to the company's heavy reliance on these specific drug treatments and the increasing competitive pressure eroding its market share, the author concludes that investors should sell their Novo Nordisk shares. The piece also notes that Novo Nordisk was excluded from the Motley Fool Stock Advisor's list of top ten stocks to buy, suggesting better opportunities exist elsewhere in the market.